Healthcare Industry News:  hysteroscopy 

Devices Surgery Product Launch

 News Release - August 16, 2018

Hologic Launches Fluent(TM) Fluid Management System for Hysteroscopic Procedures

New Technology Simplifies and Streamlines Fluid Management for Doctors and Nurses

MARLBOROUGH, Mass., Aug. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of its new Fluent™ fluid management system, featuring innovations designed to provide operating room (OR) staff more simplified and effective fluid management for hysteroscopic procedures.

"Fluid management plays a vital role in gynecological procedures, yet there have been few advances in the technology," said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic. "The Fluent system is changing the game in fluid management. Developed in response to the challenges facing nurses and doctors performing hysteroscopies, it combines a streamlined design with innovative technology for more efficient fluid monitoring during procedures."

To simplify hysteroscopic operations, the Fluent system features a single waste bag design and unique FloPak™ technology to effectively control fluid use throughout the procedure. An intuitive user interface provides step-by-step instructions for setup, disassembly and troubleshooting, and ultimately helps optimize OR workflow. In addition, large visual and audible alerts monitor fluid deficit, pressure, low fluid bags, and full waste bags to help keep procedures moving as efficiently as possible. The Fluent system experiences a change in average intrauterine pressure of less than 1% when running the MyoSure® system.[1] It also has the ability to detect accurate fluid deficit within +/- 50 mL,[2] allowing OR staff to perform hysteroscopic procedures with increased clinical confidence.

"We developed the Fluent system with a deep understanding of the hectic workflow that often characterizes the patient and staff experience," said Sean Daugherty, President of GYN Surgical Solutions, Hologic. "This launch is a testament to how our strong customer partnerships and unique technological innovations enable us to provide healthcare professionals the advanced equipment they need to improve lives."

The Fluent system helps optimize and streamline hysteroscopic workflow in combination with a wide variety of hysteroscopic devices. Equipped with an integrated MyoSure controller, the Fluent system can be an all-in-one fluid management and tissue removal system. It is designed with fluid and vacuum systems that maximize the performance of the MyoSure system.

Hologic's MyoSure suite of products includes the MyoSure REACH, MyoSure XL, MyoSure LITE, and MyoSure MANUAL devices for tissue removal in a wide range of sizes and locations. To learn more about the MyoSure suite of products, visit

For more information about the Fluent system, visit

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit

Hologic, Fluent, MyoSure, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.

Important Safety Information

The Fluent Fluid Management System is intended to provide liquid distension of the uterus during diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus while providing drive, control and suction for hysteroscopic morcellators.

The Fluent Fluid Management System may not be used to introduce fluids into the uterus when hysteroscopy is contraindicated. The system should not be used to remove pathologies from pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer. For detailed benefit and risk information, including contraindications relative to endometrial ablation, please consult the Instructions for Use.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to

[1] When operating with a MyoSure device in a bench test environment in a uterine model (N=20). Data on file, VER-08393

[2] Hologic, Inc. Data on file, bench testing. VER-07696

Source: Hologic

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.